Allos Therapeutics to Report 2007 Third Quarter Financial Results on November 5, 2007

WESTMINSTER, Colo., Oct. 16  /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (NASDAQ:ALTH) today announced that it will report 2007 third quarter financial results on Monday, November 5, 2007, before the U.S. financial markets open.

Paul L. Berns, President and Chief Executive Officer, and other members of Allos' senior management will provide a company update and discuss results via webcast and conference call on Monday, November 5, 2007 at 8:30 AM ET. The webcast of this call will be available from the homepage and the investors/media section of the Company's website, http://www.allos.com/, and will be archived for 30 days.  Alternatively, callers may participate in the conference call by dialing 888-339-9446 (domestic) or 480-629-9562 (international).  Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through Friday, November 16, 2007.  Callers can access the replay by dialing 800-406- 7325 (domestic) or 303-590-3030 (international).  The passcode is 3789950.

About Allos Therapeutics

Allos Therapeutics, Inc. (ALTH) is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 trial in patients with relapsed or refractory peripheral T-cell lymphoma. The Company is also investigating PDX in patients with non-small cell lung cancer and a range of other lymphoma sub-types. The Company's other product candidate is RH1, a targeted chemotherapeutic agent for which the Company expects to initiate a Phase 1 study in patients with advanced solid tumors in the second half of 2007. For additional information, please visit the Company's website at http://www.allos.com/.

Safe Harbor Statement

The 2007 third quarter results press release and conference call will contain forward-looking statements that involve significant risks and uncertainties, including those that can be found in the "Risk Factors" section of Allos' Form 10-K for the year ended December 31, 2006 and in Allos' periodic reports on Form 10-Q and Form 8-K. Allos is providing the information contained in the press release and conference call as of the date of the release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise. The Company cautions investors not to place undue reliance on the forward-looking statements contained in the press release or the conference call. No forward- looking statement can be guaranteed and actual events and results may differ materially from those projected. 

DATASOURCE: Allos Therapeutics, Inc.



CONTACT:  Derek Cole, Vice President, Investor Relations of Allos

Therapeutics, Inc., [phone], 



Web site:  http://www.allos.com/

Copyright